12.07.2015 Views

Navilyst Medical Awarded Contract with HealthPRO Procurement ...

Navilyst Medical Awarded Contract with HealthPRO Procurement ...

Navilyst Medical Awarded Contract with HealthPRO Procurement ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

FOR IMMEDIATE RELEASENAVILYST MEDICAL AWARDED CONTRACT WITHHEALTHPRO PROCUREMENT SERVICES, INC.Marlborough, MA (May 8, 2012) – <strong>Navilyst</strong> <strong>Medical</strong> announced today that it has signed a threeyearcontract <strong>with</strong> <strong>HealthPRO</strong> <strong>Procurement</strong> Services, Inc. to provide central venous accessdevices (Ports) and peripherally inserted central catheters (PICCs) to <strong>HealthPRO</strong>’s participatingmembers. The contract, which is effective on June 1, 2012, may be extended by <strong>HealthPRO</strong> fortwo additional one-year options.<strong>HealthPRO</strong> is Canada’s national healthcare group purchasing organization (GPO). They areinvested in Canada’s public healthcare system by representing the purchasing interests ofhospitals, provincial authorities and Shared Service Organizations (SSOs). With 255 members,including 12 of Canada’s 14 SSOs, <strong>HealthPRO</strong> brings together significant purchasing power<strong>with</strong>in Canada’s public healthcare system.“We are extremely pleased <strong>HealthPRO</strong> has selected <strong>Navilyst</strong> <strong>Medical</strong> as their supplier of choicefor Ports and PICCs,” said Ron Sparks, Chairman and CEO. “<strong>HealthPRO</strong>’s broad reach,combined <strong>with</strong> our market leading technologies, will serve to help improve the delivery and qualityof patient care throughout Canada.”As a leading provider of vascular access devices, <strong>Navilyst</strong> <strong>Medical</strong> is committed to deliveringinnovative medical devices and services to clinicians. This is evidenced by the recent launch inCanada of its BioFlo PICC <strong>with</strong> Endexo Technology. The BioFlo PICC, available <strong>with</strong><strong>Navilyst</strong> <strong>Medical</strong>’s patented PASV Valve Technology, is designed to provide a catheter moreresistant to the accumulation of blood components (platelets and thrombus). Additionally, <strong>Navilyst</strong><strong>Medical</strong> retains a highly credentialed team of Clinical Specialists providing a wide range ofeducational and support programs all designed to reinforce best practices for catheter insertionand care and maintenance.“We look forward to this joint venture <strong>with</strong> <strong>HealthPRO</strong>,” said Emilio Jimenez, VP of InternationalSales. “Our Sales and Clinical Specialist teams are poised to deliver world class service to theCanadian market.”About <strong>Navilyst</strong> <strong>Medical</strong><strong>Navilyst</strong> <strong>Medical</strong> Inc., headquartered in Marlborough, MA, is a leading provider of innovativesolutions for image-guided interventions designed to deliver superior outcomes and reducehealthcare costs for medical professionals and their patients. Its breakthrough devices includeBioFlo PICCs, available for sale in Canada and Europe, and PICCs and Ports <strong>with</strong> PASV ®Valve Technology, Xcela ® Power Injectable PICCs and world-leading NAMIC ® Fluid Managementproducts. The Company distributes its products globally and has its U.S. manufacturing facility inGlens Falls, NY. For more information, please visit: www.navilystmedical.com.


-30-FORWARD-LOOKING STATEMENTS: This Release contains forward-looking statements,including statements regarding development of <strong>Navilyst</strong> <strong>Medical</strong>’s existing and new products, theCompany’s progress toward commercial growth, and future opportunities. The Company’s actualresults may differ materially from those anticipated in these forward-looking statements basedupon a number of factors, including uncertainties associated <strong>with</strong> development, testing andrelated regulatory approvals, anticipated future losses, complex manufacturing, high qualityrequirements, dependence on limited sources of supply, competition, technological change,government regulation, future capital needs and uncertainty of additional financing, and otherrisks and challenges. Readers are cautioned not to place undue reliance on any forward-lookingstatements, which speak only as of the date of this Release. The Company undertakes noobligation to publicly release the results of any revisions to these forward-looking statements thatmay be made to reflect events or circumstances that occur after the date of this Release or toreflect the occurrence of unanticipated events.CONTACT: Jill Robinson, <strong>Navilyst</strong> <strong>Medical</strong>Phone: 508.658.7965; Email: jill.robinson@navilyst.comEndexo is a trademark of Interface BiologicsBioFlo, PASV, Xcela, NAMIC and <strong>Navilyst</strong> <strong>Medical</strong> are trademarks and/or registered trademarksof <strong>Navilyst</strong> <strong>Medical</strong>, Inc.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!